Patents Examined by Jegatheesan Seharaseyon
  • Derivatisation of granulocyte colony-stimulating factor
    Patent number: 9492557
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: November 15, 2016
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
    Patent number: 9493570
    Abstract: The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: November 15, 2016
    Assignee: MedImmune, LLC
    Inventors: Brandon Higgs, Yihong Yao, Bing Wang, Lorin Roskos, Linda Chang
  • Targeted human-interferon fusion proteins
    Patent number: 9492562
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: November 15, 2016
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Methods for treating urushiol-induced contact dermatitis
    Patent number: 9486485
    Abstract: The invention is directed to methods for treating urushiol-induced contact dermatitis. Specifically, the invention is directed to treating and reducing inflammation associated with poison ivy, poison sumac and poison oak by administering to a subject suffering from such conditions novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 8, 2016
    Assignee: STEMNION, INC.
    Inventors: Larry R Brown, Linda O Palladino
  • Leukotoxin E/D as a new anti-inflammatory agent and microbicide
    Patent number: 9480726
    Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: November 1, 2016
    Assignee: New York University
    Inventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
  • Derivatisation of granulocyte colony-stimulating factor
    Patent number: 9474805
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: October 25, 2016
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • TNF inhibitor formulation for use in implantable infusion devices
    Patent number: 9445990
    Abstract: A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: September 20, 2016
    Assignee: Medtronic, Inc.
    Inventors: Deanna S. Lane, Charlene X. Yuan, Jianwei Li, Lanchi T. Le
  • Methods for increasing forced expiratory volume in asthmatics using benralizumab
    Patent number: 9441046
    Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Methods for reducing exacerbation rates of asthma using benralizumab
    Patent number: 9441037
    Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Methods for improving asthma symptoms using benralizumab
    Patent number: 9441047
    Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Therapy for influenza like illness
    Patent number: 9421243
    Abstract: An agent selected from: (a) interferon-? (IFN-?); (b) an agent that increases IFN-? expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment is by airway delivery of said medicament.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: August 23, 2016
    Assignee: SYNAIRGEN RESEARCH LIMITED
    Inventors: Victoria Jane Tear, James Jonathan Welch Roberts, Phillip David Monk
  • Methods for reducing global chronic inflammation and the presence of melanoma
    Patent number: 9387244
    Abstract: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: July 12, 2016
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Svetomir N. Markovic
  • SorCS1 for the treatment of obesity
    Patent number: 9387232
    Abstract: The present invention relates to SorCS1-like agents, including SorCS1, nucleic acid molecule encoding expression of SorCS1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing SorCS1 and said fragments, for the treatment of obesity.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: July 12, 2016
    Assignee: Aarhus Universitet
    Inventors: Karen-Marie Pedersen, Anders Nykjaer, Mads Fuglsang Kjolby
  • Treatment methods for rheumatoid arthritis
    Patent number: 9387246
    Abstract: The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: July 12, 2016
    Inventor: L. Douglas Graham
  • Interferon analogs
    Patent number: 9381230
    Abstract: The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: July 5, 2016
    Assignee: BiOrion Technologies, B.V.
    Inventors: Klaas Poelstra, Jai Prakash, Eleonora Beljaars, Ruchi Bansal
  • Suppressor of the endogenous interferon-gamma
    Patent number: 9359421
    Abstract: The invention relates to suppressors of endogenous human interferon-gamma (INF-?) applicable in treatment of diseases associated with impaired activity of endogenous IFN-?. The suppressors of the invention are useful in treating autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. The invention includes inactive analogues or variants of IFN-? having preserved affinity to the IFN-? receptor, genetically modified in the domain responsible for triggering the signal transduction pathway.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: June 7, 2016
    Assignee: TIGO GmbH
    Inventors: Ivan Ivanov, Genoveva Nacheva, Stefan Petrov, Hans-Guenther Grigoleit
  • Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors
    Patent number: 9326993
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: ONCOGENEX TECHNOLOGIES INC.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Methods for diagnosing degenerative joint disease
    Patent number: 9322832
    Abstract: The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: April 26, 2016
    Assignee: Nestec S.A.
    Inventors: Steven Scott Hannah, Scott Sherrill, Qinghong Li, Peichuan Sun
  • IFN-beta compositions, preparation methods and uses thereof
    Patent number: 9272020
    Abstract: The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26,000 and 40,000 g/mol, grafted with alpha-tocopherol substituents, the average molar grafting ratio being 4.5-5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: March 1, 2016
    Assignee: ARES TRADING S.A.
    Inventors: Daniel Leblanc, Evert Nicolaas Lamme, Helen Gabriela Baldascini, Joel Richard, Frederic Checot, You-Ping Chan, Roger Kravtzoff, Gauthier Pouliquen
  • Derivatisation of erythropoietin (EPO)
    Patent number: 9266936
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: February 23, 2016
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf